Additional early-stage research and drug discovery news in brief, from: Alzecure Pharma, Asher Biotherapeutics, Cantargia, Genprex, JD Bioscience, Surrozen.
Mina Therapeutics Ltd. has announced a research collaboration and licensing agreement option with Nippon Shinyaku Co. Ltd. for the discovery and potential development and commercialization of small activating RNA (RNAa) therapeutic candidates targeting rare neurodegenerative diseases for which there are currently no treatment options.
Nanjing Zhongrui Medicine Co. Ltd. has described protein phosphatase 2A (PP2A) activators reported to be useful for the treatment of Alzheimer’s disease.
Scientists at Nikang Therapeutics Inc. and Shanghai Blueray Biopharma Co. Ltd. have identified tetracyclic derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
Arvinas Operations Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds consisting of a cereblon E3 ubiquitin ligase binding moiety coupled to a Raf kinase B G466V and/or V600E mutant targeting agent through a linker.
Caris Discovery, the therapeutic research arm of Caris Life Sciences Inc., has established a multiyear strategic partnership with Merck KGaA to accelerate the discovery and development of first-in-class antibody-drug conjugates for cancer patients.
Aethon Therapeutics Inc. has entered into a collaboration agreement with Revolution Medicines Inc. under which Aethon will use its Hapimmune platform to discover novel bispecific antibodies to mount an immune attack directed towards cancer cells hit by Revolution Medicines’ RAS(ON) inhibitors.
It has been previously demonstrated that insulin-reactive B cells act as antigen-presenting cells to promote type 1 diabetes by stimulating pathogenic T cells and leading to destruction of insulin-producing beta cells of pancreatic islets.
RSS
